Managing thromboembolic risk with menopausal hormone therapy and hormonal contraception in the COVID-19 pandemic: Recommendations from the Spanish Menopause Society, Sociedad Española de Ginecología y Obstetricia and Sociedad Española de Trombosis y Hemostasia
Authors:
- Isabel RamírezIRIsabel Ramírez
- Esther De la ViudaEVEsther De la Viuda
- Laura BaquedanoLBLaura Baquedano
- Pluvio CoronadoPCPluvio Coronado
- Plácido LlanezaPLPlácido Llaneza
- Nicolás MendozaNicolás Mendoza
- Borja OteroBOBorja Otero
- Sonia SánchezSSSonia Sánchez
- Mª Jesús CanceloMCMª Jesús Cancelo
- José Antonio PáramoJPJosé Antonio Páramo
- Antonio CanoACAntonio Cano
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databasesBMJ, 2019
- How do you decide on hormone replacement therapy in women with risk of venous thromboembolism?Blood Reviews, 2017
- Oral vs Transdermal Estrogen Therapy and Vascular Events: A Systematic Review and Meta-AnalysisThe Journal of Clinical Endocrinology & Metabolism, 2015
- Classical and newly recognised non-contraceptive benefits of combined hormonal contraceptive use in women over 40Maturitas, 2014
- Spanish Menopause Society position statementMenopause, 2013
- Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective studyJournal of Thrombosis and Haemostasis, 2012
- Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysisBMJ, 2012
- Thrombotic Stroke and Myocardial Infarction with Hormonal ContraceptionNew England Journal of Medicine, 2012
- Venous and pulmonary thromboembolism and combined hormonal contraceptives. Systematic review and meta-analysisThe European Journal of Contraception & Reproductive Health Care, 2012
- Developing clinical guidelines.1999